Bakakos Agamemnon, Schleich Florence, Bakakos Petros
Department of Respiratory Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
Department of Respiratory Medicine, University of Liege, GIGA I3, 4000 Liege, Belgium.
J Pers Med. 2022 Jun 16;12(6):976. doi: 10.3390/jpm12060976.
Chronic rhinosinusitis is a common disease worldwide and can be categorized into chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis with nasal polyps is common in patients with asthma and, particularly, severe asthma. Severe asthma is effectively treated with biologics and the coexistence of severe asthma with chronic rhinosinusitis with nasal polyps presents a phenotype that is more likely to respond to such treatment. In this review, we focus on the link between asthma and nasal polyps, and we review the treatment effect of various monoclonal antibodies in patients with severe asthma and nasal polyps as well as in patients with nasal polyps without asthma or with mild-to-moderate asthma. With the enhancement of our armamentarium with new monoclonal antibodies the right choice of biologic becomes an important target and one that is difficult to achieve due to the lack of comparative head-to-head studies.
慢性鼻窦炎是一种全球常见疾病，可分为伴有鼻息肉的慢性鼻窦炎和不伴有鼻息肉的慢性鼻窦炎。伴有鼻息肉的慢性鼻窦炎在哮喘患者中很常见，尤其是重度哮喘患者。生物制剂可有效治疗重度哮喘，重度哮喘与伴有鼻息肉的慢性鼻窦炎并存呈现出一种更可能对这种治疗产生反应的表型。在本综述中，我们重点关注哮喘与鼻息肉之间的联系，并综述各种单克隆抗体对重度哮喘合并鼻息肉患者以及无哮喘或轻度至中度哮喘的鼻息肉患者的治疗效果。随着我们可用的新型单克隆抗体武器库的扩充，生物制剂的正确选择成为一个重要目标，但由于缺乏对比性的直接比较研究，这一目标难以实现。
